Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
National Seating & Mobility Gets New PE Investor
Cinven, the London-based private equity firm, struck a deal last week to acquire National Seating & Mobility (NMS) from Court Square Capital Partners. The sale, which was valued at $850 million by sources cited in PEHub Buyouts, resulted from a Harris Williams-run auction that began in August. Court Square Capital bought it from Wellspring Capital Management in 2016, but now Cinven will be backing the company. NMS provides complex rehab technology (CRT) solutions focusing on highly customized wheelchairs for patients diagnosed with long-term or permanent loss of mobility. NMS operates through Rehab Technician Specialist (RTS) which connects with physicians and physical therapists. The... Read More »
Ra Pharmaceuticals Targeted in $2.1 Billion Acquisition
The global biopharmaceutical company UCB (Brussels: UCB) announced it is acquiring Ra Pharmaceuticals (NASDAQ: RARX) for $2.1 billion. Ra Pharma is a clinical-stage biopharmaceutical company that develops novel therapeutics for the treatment of serious diseases caused by excessive or uncontrolled activation of the complement system, a critical component of the innate immune system. Ra Pharmaceuticals shareholders will receive $48.00 for each held share (approx. $2.5 billion or EUR 2.2 billion), with transaction value at $ 2.1 billion or EUR 2 billion, net of Ra Pharma cash. Ra Pharma reported a trailing 12-month revenue of $2.5 million. This acquisition will give UCB a number of high-value... Read More »
Home Health & Hospice Sector Deals Dipped in Q3:19
Deal volume in the home health and hospice sector dipped slightly in the third quarter of 2019, down 23% with 20 publicly announced transactions, compared with 26 acquisitions in the second quarter, according to data from HealthCareMandA.com. Compared with the third quarter of 2018, home health and hospice M&A activity decreased by 20%, when 25 acquisitions were announced. Six of the transactions disclosed prices in the third quarter of 2019, for a combined total of nearly $1.2 billion. In the same quarter of 2018, the total dollar value based on disclosed prices was just $7.2 million. Of the 20 transactions announced in the third quarter, 35% were announced by private equity firms or... Read More »
Mednax Sells MedData, Pulls Back on M&A
It’s been nearly a year since Mednax Inc. (NYSE: MD) announced its MedData subsidiary was headed for the auction block. The company acquired the privately held revenue cycle management company in August 2014 for an undisclosed amount. Now that Mednax has hired teams of consultants to help it rethink its business model, MedData is a non-core asset. Frazier Healthcare Partners agreed to pay $250 million for MedData in mid-October, although Mednax has classified MedData as discontinued operations since the first quarter of 2019. The target provides management services to hospitals, health systems and healthcare providers. Back in 2014, when Mednax bought it, MedData served 3,000 physicians at... Read More »
Health Care M&A Deals, Week Ending October 11, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Behavioral Health Care Acquirer Target Price Maryland Addiction Recovery Center and Caron Treatment Centers Encore Recovery Solutions N/A Biotechnology Acquirer Target Price UCB S.A. Ra Pharmaceuticals $2,100,000,000 eHealth Acquirer Target Price General Atlantic LLC... Read More »
Health Care M&A Deals, Week Ending October 4, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price Health Sciences Acquisitions Corporation Immunovant Sciences Ltd. $395,000,000 eHealth Acquirer Target Price Quake Global, Inc. Skynet Healthcare Technologies Inc. N/A Francisco Partners Orchard Software Corporation N/A Pharmagest Group Svemu N/A Home Health Care & Hospice... Read More »
Sobi Grows Product Portfolio With 2nd Deal
Swedish Orphan Biovitrum AB (STO: SOBI), an international specialty healthcare company dedicated to rare diseases, announced its acquisition of Dova Pharmaceuticals, Inc. for $867.7 million (65.3x revenue), or 27$ per share. Dova acquires, develops and commercializes drug candidates for diseases such as thrombocytopenia, a condition that leaves an individual with a low blood platelet count. Its primary candidate, Doptelet, is pending approval for the treatment of chemotherapy-induced thrombocytopenia (CIT). A CVR worth $1.50 per share will be granted if Doptelet is approved, totaling a potential $915 million. An indirect subsidiary of Sobi is acquiring Dove to bolster its hematology and... Read More »
TowerBrook & Ascension Acquire Hospice Compassus in $1 Billion Deal
TowerBrook Capital Partners and Ascension have joined forces in a hospice deal worth $1 billion, or 11.8x revenue. The joint venture is buying Hospice Compassus, which provides hospice, palliative and home health care and services to patients in more than 25 states, from Formation Capital and Audax Private Equity. Towerbrook and Ascension will own equal stakes in Hospice Compassus after buying the hospice firm an auction that started in early 2019. Formation and Audax backed Hospice Compassus for roughly five years, recapitalizing the company in 2014 for roughly $300 million, according to the same report. Although it’s no surprise that PE firms are big players in the Home Health and... Read More »
Healthcare Deals in Q3:19 Slowed, but Held Steady
Looking back, the third quarter got off to a great start. The Dow topped 27,000 and the S&P 500 passed 3,000 within the first two weeks. The NASDAQ followed, rising past 8,000 in about three weeks from the start. All were boosted by the Fed’s lowering its interest rate by a quarter point at its July meeting. Another rate drop followed in September, but by then, the markets were recovering from the chaos that hit in August. Through it all, healthcare deals held steady. Early results show the third quarter’s deal volume remained strong, with 396 deals now on the books. That preliminary figure is 15% lower than the 468 deals announced in Q2:19 and 17% behind the same quarter in 2018, when... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
